Sunday, May 9, 2021

At the request of the EU, EMA revises data on AstraZeneca vaccine

Facebook
Twitter
Pinterest
WhatsApp
Telegram

Must Read

Luong Thai Linh / EPA

The European Medicines Agency (EMA) announced on Wednesday that it is reviewing data on the Vaxzevria vaccine at the request of the European Commission.

According to a statement quoted by the Observer, the European Medicines Agency (EMA) is reviewing vaccination data and data on the epidemiology of the disease, including infection rates, hospitalizations, morbidity and mortality ”following a meeting of ministers of the European Union (EU).

The review of the EMA’s Human Medicines Committee (CHMP) will allow authorities to “put the risks of the Vaxzevria vaccine in the context of the benefits vaccination campaigns ”that are taking place in the different Member States.

“The CHMP will also consider updating recommendations for the second dose of Vaxzevria in people who have already received the first dose” of this vaccine, according to the EMA.

Thus, the review will allow to support national vaccination campaigns on the best way to administer this vaccine.

The EU’s vaccination campaign has been marked by delays the delivery of vaccines by the Anglo-Swedish pharmaceutical company AstraZeneca and the side effects of its drug, given the confirmed link to very rare cases of blood clots.

On April 8, the Portuguese health authorities recommended the administration of the AstraZeneca vaccine in people over 60 years of age.

This Wednesday, the Italian newspaper The print advanced that the European Commission decided that the contracts with companies producing vaccines with viral vectors valid for the current year will not be renewed. Vaccines against covid-19 from AstraZeneca and Johnson & Johnson fall into this type of vaccine.

Johnson & Johnson also said that the distribution of the covid-19 vaccine will be delayed in Europe after the Food and Drug Administration (FDA) and the United States Center for Disease Control (CDC) have requested an immediate pause. in the use of the Johnson & Johnson vaccine because they were detected six cases of blood clots.

Currently, four vaccines are approved in the EU: Comirnaty (trade name of the Pfizer / BioNTech vaccine), Moderna, Vaxzevria (new name for the AstraZeneca vaccine) and Janssen.

Maria Campos Maria Campos, ZAP //

Facebook
Twitter
Pinterest
WhatsApp
Telegram

Latest News

Bahia wins Ceará on penalties and wins the Northeast Cup’s fourth championship – Prime Time Zone

With that, the tricolor club reached its fourth title, the same number as its arch-rival Vitória; Ceará has...

More Articles Like This

spot_img